What is the significance of an M band in the gamma region on serum protein electrophoresis (SPEP) in multiple myeloma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is the M Band in Multiple Myeloma?

The M band (or M-spike) is an abnormal sharp peak that appears on serum protein electrophoresis (SPEP), typically in the gamma region, representing a large amount of identical abnormal antibodies (monoclonal protein) produced by cancerous plasma cells in multiple myeloma. 1

Understanding the M Band in Simple Terms

What it represents:

  • The M band is a visual marker of a monoclonal protein (M-protein) - a single type of abnormal antibody made by a clone of cancerous plasma cells 1, 2
  • Think of it as a "fingerprint" of the cancer: normal plasma cells make many different types of antibodies (creating a broad, diffuse pattern), but myeloma cells make massive amounts of just one identical antibody (creating a sharp, narrow spike) 3, 2

Where it appears:

  • Most commonly in the gamma globulin region of the electrophoresis pattern (the rightmost area on the graph) 1, 4
  • Less commonly in the beta region 5, 6
  • Rarely in the alpha-2 region 7

Clinical Significance

Diagnostic value:

  • Detection of an M band on SPEP is a fundamental step in diagnosing multiple myeloma and must be followed by immunofixation to characterize which specific antibody type (IgG, IgA, IgM) and light chain (kappa or lambda) is being produced 1, 2
  • The M band helps distinguish multiple myeloma from other conditions: a discrete sharp peak suggests a monoclonal process (potentially myeloma), while a broad elevation suggests polyclonal increase from inflammation or infection 3

Quantification matters:

  • The height and area under the M-spike can be measured to quantify how much abnormal protein is present 8, 4
  • In MGUS (a benign precursor condition), the M-protein is less than 30 g/L, while in multiple myeloma it is typically higher 1

Important Caveats

Not all myeloma shows an M band:

  • Approximately 15-20% of myeloma cases produce only light chains (not complete antibodies), which may not create a visible spike on standard SPEP and require urine testing or serum free light chain assays for detection 9, 2
  • Some cases are truly "non-secretory" and produce no detectable M-protein at all 1, 9

Unusual presentations:

  • Rarely, a single myeloma can produce two M bands (appearing like two separate peaks) due to polymeric forms of the same antibody - this can be mistaken for two different cancers but is actually one 5, 6
  • The M band location can vary: while gamma region is most common, beta and even alpha-2 region spikes can occur 5, 7

Next Steps After Finding an M Band

Essential follow-up testing includes: 1, 2

  • Immunofixation electrophoresis to identify the exact type of M-protein
  • Quantitative immunoglobulin levels (IgG, IgA, IgM)
  • Serum free light chain assay with kappa/lambda ratio
  • 24-hour urine collection for urine protein electrophoresis
  • Bone marrow biopsy to assess plasma cell percentage
  • Complete blood count, calcium, creatinine to check for organ damage
  • Skeletal survey to look for bone lesions

Referral urgency: 2

  • Any detected M-protein warrants hematology/oncology referral within 1-2 weeks if accompanied by symptoms, anemia, kidney dysfunction, or elevated calcium

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Serum Protein Electrophoresis in Plasma Cell Disorders

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Polyclonal Increase in Immunoglobulins on SPEP

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnostic and Treatment Approach for Multiple Myeloma with Negative Serum Paraprotein

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.